Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Chem Biol Interact ; 229: 64-72, 2015 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-25641192

RESUMEN

It has been reported that various metal coordination compounds have improved some biological properties. A high activity of acid phosphatase (AcP) is associated to several diseases (osteoporosis, Alzheimer's, prostate cancer, among others) and makes it a target for the development of new potential inhibitors. Anti-thyroid agents have disadvantageous side effects and the scarcity of medicines in this area motivated many researchers to synthesize new ones. Several copper(II) complexes have shown antifungal activities. In this work we presented for a first time the inhibition of AcP and the anti-thyroid activity produced by methimazole-Cu(II) complexes. Cu-Met ([Cu(MeimzH)2(H2O)2](NO3)2·H2O) produces a weak inhibition action while Cu-Met-phen ([Cu(MeimzH)2(phen)(H2O)2]Cl2) shows a strong inhibition effect (IC50 = 300 µM) being more effective than the reported behavior of vanadium complexes. Cu-Met-phen also presented a fairly good anti-thyroid activity with a formation constant value, Kc=1.02 × 10(10)M(-1) being 10(6) times more active than methimazole (Kc = 4.16 × 10(4)M(-1)) in opposition to Cu-Met which presented activity (Kc=9.54 × 10(3)M(-1)) but in a lesser extent than that of the free ligand. None of the complexes show antifungal activity except Cu-phen (MIC = 11.71 µgmL(-1) on Candidaalbicans) which was tested for comparison. Besides, albumin interaction experiments denoted high affinity toward the complexes and the calculated binding constants indicate reversible binding to the protein.


Asunto(s)
Fosfatasa Ácida/antagonistas & inhibidores , Antifúngicos/farmacología , Antitiroideos/farmacología , Complejos de Coordinación/farmacología , Cobre/farmacología , Metimazol/farmacología , Albúmina Sérica Bovina/metabolismo , Fosfatasa Ácida/metabolismo , Animales , Antifúngicos/química , Antitiroideos/química , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Bovinos , Complejos de Coordinación/química , Cobre/química , Humanos , Metimazol/química , Conformación Proteica/efectos de los fármacos , Albúmina Sérica Bovina/química
2.
Biometals ; 23(2): 255-64, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20012553

RESUMEN

Methimazole (MeimzH) is an anti-thyroid drug and the first choice for patients with Grave's disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)(2)(NO(3))(2)]*0.5H(2)O and [Cu(MeimzH)(2)(H(2)O)(2)](NO(3))(2)*H(2)O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.


Asunto(s)
Fosfatasa Alcalina/antagonistas & inhibidores , Antitiroideos/síntesis química , Antitiroideos/metabolismo , Antitiroideos/uso terapéutico , Cobre/química , Enfermedad de Graves/tratamiento farmacológico , Metimazol/síntesis química , Metimazol/metabolismo , Metimazol/uso terapéutico , Animales , Antitiroideos/química , Espectroscopía de Resonancia por Spin del Electrón , Humanos , Metimazol/química , Espectrofotometría Ultravioleta , Espectroscopía Infrarroja por Transformada de Fourier
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA